Back to search

Article

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

2026-03-18

Abstract excerpt

<title>Abstract</title> <p>Background Germline BRCA1/2-mutated (gBRCAm) hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer (MBC) represents a biologically distinct subset in which the efficacy of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors remains incompletely characterized. Given the interplay between DNA damage repair deficiency and cell-cycle regulation, BRCA-associated tumors ma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
26283d80-1700-582a-af5b-5aebd40d3bc0
DOI
10.21203/rs.3.rs-9066080/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudyDOI 10.21203/rs.3.rs-9066080/v1
Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world StudySemantic proximity
Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity
Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapySemantic proximity
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity
TP53 mutation is associated with resistance to CDK4/6 Inhibitors, but not to Immune Checkpoint Inhibitors, in ER-positive/HER2-negative Breast Cancer: Real-World perspectiveSemantic proximity
Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world databaseSemantic proximity
The Present and Future of Clinical Management in Metastatic Breast CancerSemantic proximity
Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerSemantic proximity
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.Semantic proximity
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.Semantic proximity
Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multi- institutional Retrospective Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.